...Thank you, Mike. Good afternoon, everyone, and thank you for joining us. As expected, the third quarter of 2022 was an active period for both of our lead programs, sotagliflozin, our dual SGLT1 and 2 inhibitor that we're developing for heart failure and LX9211, our AAK1 inhibitor that we are developing for neuropathic pain. Let me jump in and tell you that I'm very pleased to report, we had our mid-cycle review meeting with the FDA earlier this week for our NDA for sotagliflozin for the treatment of heart failure. The agency indicated that there were no significant review issues that may impact approvability of the NDA, it has identified no major safety concerns and that it has no plans to hold an advisory committee meeting. So everything remains on track for an anticipated PDUFA target action date in May of 2023. We continue to believe the unique data from our SOLOIST-WHF trial in recent and worsening heart failure may provide a point of differentiation and strong entry into the heart...
